Suppr超能文献

用于指导手术可切除性和预后的PCC分期系统的利弊。

The pros and cons of the PCC staging system to guide surgical resectability and prognosis.

作者信息

Liu Pei, Song Yinghui, Shakoor Kashif, Peng Chuang, Liu Sulai

机构信息

Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University; Changsha 410005, China.

Central Laboratory of Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China.

出版信息

J Cancer. 2022 Oct 9;13(13):3444-3451. doi: 10.7150/jca.76696. eCollection 2022.

Abstract

Perihilar cholangiocarcinoma (PCC) is a malignant mass originating from the bile ducts. There is currently no unified treatment plan, and there are various treatment methods applied in clinical practice, as well as several different staging and typing systems to guide resectability, prognosis and survival prediction. The choice of treatment for PCC is closely related to the stage of the tumor. Accurate preoperative staging is necessary for correct resectability assessment and the selection of a reasonable treatment plan and surgical method; similarly, accurate postoperative pathological staging is necessary to guide further treatment and judgment of the patient's prognosis. A universally accepted staging system facilitates the comparison of cases between different centers, but there is much debate about the classification and staging of PCC. At present, the existing staging systems include the Bismuth-Corlette classification, AJCC/UICC TNM staging, modified T staging, Gazzaniga staging, JSBS staging, and Mayo staging. Each system has advantages, but there is no comprehensive guide for tumor resectability, prognosis, and survival. In this paper, the pros and cons of the different systems for staging PCC in terms of resectability, prognosis and survival prediction are discussed.

摘要

肝门部胆管癌(PCC)是一种起源于胆管的恶性肿瘤。目前尚无统一的治疗方案,临床实践中应用的治疗方法多种多样,还有几种不同的分期和分型系统用于指导可切除性、预后及生存预测。PCC的治疗选择与肿瘤分期密切相关。准确的术前分期对于正确评估可切除性、选择合理的治疗方案和手术方法至关重要;同样,准确的术后病理分期对于指导进一步治疗和判断患者预后也很有必要。一个被普遍接受的分期系统有助于不同中心之间病例的比较,但关于PCC的分类和分期存在很多争议。目前,现有的分期系统包括Bismuth-Corlette分类、AJCC/UICC TNM分期、改良T分期、Gazzaniga分期、JSBS分期和Mayo分期。每个系统都有优点,但对于肿瘤的可切除性、预后及生存情况均缺乏全面的指导。本文讨论了不同PCC分期系统在可切除性、预后及生存预测方面的优缺点。

相似文献

1
The pros and cons of the PCC staging system to guide surgical resectability and prognosis.
J Cancer. 2022 Oct 9;13(13):3444-3451. doi: 10.7150/jca.76696. eCollection 2022.
2
Superiority of clinical American Joint Committee on Cancer T classification for perihilar cholangiocarcinoma.
J Hepatobiliary Pancreat Sci. 2022 Jul;29(7):768-777. doi: 10.1002/jhbp.1066. Epub 2021 Nov 9.
3
[TNM staging of hilar cholangiocarcinoma].
Korean J Gastroenterol. 2005 Jul;46(1):20-7.
5
Evaluation of UICC-TNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma.
Langenbecks Arch Surg. 2010 Aug;395(6):615-23. doi: 10.1007/s00423-010-0640-3. Epub 2010 Apr 1.
7
Staging of extrahepatic cholangiocarcinoma.
Eur Radiol. 2008 Oct;18(10):2182-95. doi: 10.1007/s00330-008-1006-x. Epub 2008 May 6.
9
TNM classification for perihilar cholangiocarcinoma: comparison between 5th and 6th editions of the AJCC/UICC staging system.
Langenbecks Arch Surg. 2005 Aug;390(4):319-27. doi: 10.1007/s00423-005-0561-8. Epub 2005 Jul 7.
10

本文引用的文献

1
The new insight of treatment in Cholangiocarcinoma.
J Cancer. 2022 Jan 1;13(2):450-464. doi: 10.7150/jca.68264. eCollection 2022.
2
Horizons on the Therapy of Biliary Tract Cancers: A State-of-the-art Review.
J Clin Transl Hepatol. 2021 Aug 28;9(4):559-567. doi: 10.14218/JCTH.2021.00007. Epub 2021 May 12.
3
Laparoscopic versus open surgery for hilar cholangiocarcinoma: a retrospective cohort study on short-term and long-term outcomes.
Surg Endosc. 2022 Jun;36(6):3721-3731. doi: 10.1007/s00464-021-08686-6. Epub 2021 Aug 16.
4
Transhepatic hilar approach for Bismuth types III and IV perihilar cholangiocarcinoma with long-term outcomes.
J Int Med Res. 2021 May;49(5):3000605211008336. doi: 10.1177/03000605211008336.
6
Application of Laparoscopic Radical Resection for Type III and IV Hilar Cholangiocarcinoma Treatment.
Gastroenterol Res Pract. 2020 Feb 25;2020:1506275. doi: 10.1155/2020/1506275. eCollection 2020.
8
Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma.
J Gastrointest Surg. 2020 Jul;24(7):1612-1618. doi: 10.1007/s11605-019-04127-x. Epub 2019 Feb 12.
9
Successful Resection in a Case of Hepatocellular Carcinoma Masquerading as Hilar Cholangiocarcinoma: A Case Report.
J Clin Transl Hepatol. 2018 Dec 28;6(4):442-446. doi: 10.14218/JCTH.2018.00038. Epub 2018 Oct 7.
10
Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma.
Ann Surg Oncol. 2019 Feb;26(2):611-618. doi: 10.1245/s10434-018-7075-4. Epub 2018 Dec 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验